title: Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis.
abstract: BACKGROUND
  About 1 in 3 women taking alendronate for osteoporosis report gastrointestinal symptoms, a rate much higher than that found during clinical trials.
  
  
  OBJECTIVE
  To establish the frequency of outpatient visits and hospital admissions for acid-related upper gastrointestinal disorder (ARD) among women taking alendronate and to identify potential risk factors.
  
  
  METHODS
  A retrospective database analysis identified 812 women with osteoporosis who had filled one or more 10-mg alendronate prescriptions from October 1995 through October 1996.
  
  
  RESULTS
  One hundred (12.3%) of the 812 women received healthcare for ARD, a clinical encounter rate of 28.5 per 100 person-years. A reference group of 362,109 women from the same health plan had 17.6 ARD encounters per 100 person-years. Excluding women who had ARDs before receiving alendronate, alendronate users were 1.6 (95% CI = 1.2, 2.7) times more likely to have an ARD encounter than nonusers. Risk of having ARD increased with age [users aged 70 years and older had a relative risk of 1.5 (95% confidence interval (CI) 1.0-2.30) compared with younger women] and with concurrent use of nonsteroidal anti-inflammatory drugs (NSAIDS) (relative risk 1.7, 95% CI 1.1-2.6).
  
  
  CONCLUSIONS
  Elderly alendronate users or those concurrently taking NSAIDS should be carefully monitored because of their high risk of having ARD. Cost/benefit analyses of alendronate treatment for osteoporosis should include costs of treating ARD.
authors.affiliation: Division of Research, Kaiser Permanente Medical Care Program, CA 94611-5714, USA.
authors.forename: B
authors.initials: B
authors.lastname: Ettinger
authors.forename: A
authors.initials: A
authors.lastname: Pressman
authors.forename: J
authors.initials: J
authors.lastname: Schein
mesh_terms: D000368:Aged; D019386:Alendronate / Q000009:adverse effects*; D002140:California / Q000453:epidemiology; D005260:Female; D005764:Gastroesophageal Reflux / Q000139:chemically induced / Q000628:therapy*; D006279:Health Maintenance Organizations / Q000706:statistics & numerical data*; D006801:Humans; D015994:Incidence; D008875:Middle Aged; D009819:Office Visits / Q000706:statistics & numerical data*; D010024:Osteoporosis / Q000188:drug therapy*; D010343:Patient Admission / Q000706:statistics & numerical data*; D012189:Retrospective Studies
chemical_list: D019386:Alendronate